Hangzhou Tigermed Consulting Co., Ltd. Class A · SZSE:300347
Hangzhou Tigermed Consulting Co., Ltd. Class A — H1 2021 Earnings Presentation
23 slides from Hangzhou Tigermed Consulting Co., Ltd. Class A's earnings presentation, August 2021
Slide 1: Hangzhou Tigermed Consulting Co., Ltd.
Hangzhou Tigermed Consulting Co., Ltd. 300347.SZ / 3347.HK August 2021
Slide 2: Disclaimer
Disclaimer This document is for information purposes only and is not intended to provide any representation, in whole or in part, of the relevant matters. Please refer to the 2021 interim results announcement and other relevant announcements published on the websites of the Shenzhen Stock Exchange (
Slide 3: 2021 Interim Results
2021 Interim Results
Slide 4: 1H2021 Key Financials Update
1H2021 Key Financials Update Adjusted Net Profit Attributable to the Revenue Gross Profit and Margin Owners of the Company and Margin(1) (RMB mm) (RMB mm) 48.1% 47.0% (RMB mm) 28.1% 33.7% 2,056.4 1H20’-1H21’ 966.9 YoY Growth 1,452.0 1,022.8 +38.0% 692.1 698.1 741.0 407.7 1,033.6 +45.4% 711.0 1H2020
Slide 5: Further Normalization Seen on Our Growth Trajectory
Further Normalization Seen on Our Growth Trajectory Total revenue grew at a CAGR of 24.4% between 1H2019 and 1H2021 Clinical Trial Solutions Revenue Clinical-related and Laboratory Services Revenue (RMB mm) (RMB mm) 1,033.6 1,022.8 932.1 808.2 755.7 741.0 719.4 711.0 700.9 627.3 1H2019 2H2019 1H2020
Slide 6: Strong New Booking Recorded during 1H2021
Strong New Booking Recorded during 1H2021 New Bookings (RMB mm) 5,074.8 2,023.3 1H2020 1H2021 3
Slide 7: Revenue Breakdown by PRC and Overseas Markets
Revenue Breakdown by PRC and Overseas Markets PRC Revenue Overseas Revenue (RMB mm) (RMB mm) 1,110.8 945.6 845.8 606.2 1H2020 1H2021 1H2020 1H2021 Revenue Breakdown by Region ◼ PRC revenue continued its steady growth during 1H2021. Business negatively impacted by the pandemic, including site managem
Slide 8: Cost of Services
Cost of Services Cost of Services Breakdown by Nature and as % of Revenue (RMB mm) 51.9% 53.0% 1,089.5 7.7% 753.9 15.8% 6.8% 15.1% 29.5% 30.0% 1H2020 1H2021 Direct labor costs Direct project-related costs Overhead costs 5
Slide 9: Operating Expenses
Operating Expenses Selling and Marketing Expenses and as % of Revenue Administrative Expenses and as % of Revenue (RMB mm) (RMB mm) 2.7% 3.2% 12.8% 12.0% 246.7 186.1 66.7 39.8 1H2020 1H2021 1H2020 1H2021 R&D Expenses and as % of Revenue Share-based Compensation and as % of Revenue (RMB mm) (RMB mm)
Slide 10: Business Update
Business Update Diigermed
Slide 11: Clinical Trial Solutions ("CTS")
Clinical Trial Solutions (“CTS”) Revenue (RMB mm) 1,033.6 ◼ The increase of CTS revenue was primarily contributed by the increased revenue from our clinical trial operation services. 711.0 ◼ The growth of our clinical trial operation business accelerated during 1H2021 as we received continuing deman
Slide 12: CTS Key Business Updates
CTS Key Business Updates Number of Ongoing Drug Clinical Research Projects by Phase(1) Number of Ongoing Drug Clinical Research Projects by Region(1) 491 491 37 29 389 39 389 111 349 28 349 20 21 28 137 17 24 95 117 85 107 85 66 351 74 247 274 193 123 150 06/30/2020 12/31/2020 06/30/2021 06/30/2020
Slide 13: Leadership Position in China Clinical CRO Market Strengthened
Leadership Position in China Clinical CRO Market Strengthened Top 30 CROs with most international collaboration filings(1) with HGRAC(2) during 1H2021 101 c. 21% of total filings 1. 238 CROs involved in 920 filings out of a total of 1,725 international collaboration filings 89 with HGRAC during 1H20
Slide 14: Clinical-related and Lab Services ("CRLS")
Clinical-related and Lab Services (“CRLS”) Revenue (RMB mm) ◼ Continuing increase in demand of CRLS services including laboratory services, site management and Data Management and Statistical Analysis 1,022.8 (“DMSA”) services and the recovery from the pandemic on our CRLS business as compared with
Slide 15: CRLS Key Business Updates
CRLS Key Business Updates Data Management and Statistical Analysis Site Management Laboratory Services Projects completed Conducted by 228 team based overseas 2,417 1,329 1,994 Completed Completed 1,581 Conducted by 1,512 453 team based in China 127 158 105 103 148 122 2018 2019 2020 06/30/2021 2018
Slide 16: Overseas Business Updates
Overseas Business Updates Number of Overseas Employees(1) 854 ◼ 111 ongoing single region overseas clinical trials as of 30 June 2021, 772 primarily in South Korea, Australia and the US 731 ◼ 29 ongoing MRCTs as of 30 June 2021 covering countries across North America, Asia Pacific, Europe and LatAm
Slide 17: Updates of Investment Activities
Updates of Investment Activities Realized Investment Gain and Fair Value Gain(1) (RMB mm) ▪ Portfolio included 107 companies in the 906.1 healthcare industry and 53 investment funds as of June 30, 2021 ▪ RMB 7,086.4mm balance as of 30 June 2021 632.7 ▪ Invested RMB 781.2mm in unlisted equities and d
Slide 18: Employee Base
Employee Base Total employees increased 19.5% to 7,208 as of June 30, 2021 from 6,032 as of December 31, 2020 Employees Mix by Function as of June 30, 2021 Employees Mix by Geography as of June 30, 2021 Management and administration Overseas (including Hong Kong, Macau and Taiwan) Marketing and 381
Slide 19: Appendix
Appendix
Slide 20: Consolidated Statement of Profit or Loss
Consolidated Statement of Profit or Loss Six months ended June 30, (RMB 000s) 2020 2021 Revenue 1,451,994 2,056,375 Cost of services (753,880) (1,089,456) Gross profit 698,114 966,919 Other income 31,878 147,419 Other gains and losses, net 752,247 1,007,221 Impairment losses (5,811) (10,252) Selling
Slide 21: Consolidated Statement of Financial Position
Consolidated Statement of Financial Position (RMB 000s) As of December 31, 2020 As of June 30, 2021 NON-CURRENT ASSETS 7,862,049 9,763,927 Property, plant and equipment 400,455 531,976 Intangible assets 124,782 114,195 Goodwill 1,444,519 1,463,189 Right-of-use assets 332,615 382,906 Interests in ass
Slide 22: Consolidated Statement of Financial Position (Cont'd)
Consolidated Statement of Financial Position (Cont’d) (RMB 000s) As of December 31, 2020 As of June 30, 2021 CURRENT LIABILITIES 1,139,337 1,450,722 Trade and other payables 529,546 670,379 Contract liabilities 484,643 626,930 Income tax payables 72,858 92,307 Lease liabilities 52,290 61,106 NON-CUR
Slide 23: 300347.SZ 3347.HK
300347.SZ 3347.HK Hangzhou Tigermed Consulting Co., Ltd. www.tigermedgrp.com
Hangzhou Tigermed Consulting — H1 2021 Earnings Presentation on 6ix